Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial

IMPORTANCE: The global prevalence of myopia is predicted to approach 50% by 2050, increasing the risk of visual impairment later in life. No pharmacologic therapy is approved for treating childhood myopia progression. OBJECTIVE: To assess the safety and efficacy of NVK002 (Vyluma), a novel, preserva...

Descripción completa

Detalles Bibliográficos
Autores principales: Zadnik, Karla, Schulman, Erica, Flitcroft, Ian, Fogt, Jennifer S., Blumenfeld, Louis C., Fong, Tung M., Lang, Eric, Hemmati, Houman D., Chandler, Simon P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236322/
https://www.ncbi.nlm.nih.gov/pubmed/37261839
http://dx.doi.org/10.1001/jamaophthalmol.2023.2097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236322/
https://www.ncbi.nlm.nih.gov/pubmed/37261839
http://dx.doi.org/10.1001/jamaophthalmol.2023.2097

Ejemplares similares